560P Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC

达布拉芬尼 医学 奥西默替尼 曲美替尼 癌症研究 突变体 肿瘤科 突变 靶向治疗 内科学 表皮生长因子受体 激酶 埃罗替尼 MAPK/ERK通路 基因 威罗菲尼 遗传学 癌症 黑色素瘤 生物 转移性黑色素瘤
作者
C. Weng,Kejing Tang,Shijie Jin,Chenfei Zhou,Yueliang Yao,J-W. Su,Huarong Chen,Kan Liu,Yuan Li,Jin‐Ji Yang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1688-S1688
标识
DOI:10.1016/j.annonc.2023.10.638
摘要

This study represents, to our knowledge, the first cohort study investigation into the efficacy and safety of a triple-targeted therapy comprising EGFR/BRAF/MEK inhibitors dabrafenib, trametinib and osimertinib for NSCLC patients with acquired BRAF V600E mutation after EGFR-TKI treatment. Patient-derived organoid (PDO) experiments were conducted to further elucidate the drug response. A retrospective review of medical records was performed in multi-centers to analyze EGFR-mutant advanced NSCLC patients who developed acquired BRAF V600E mutation following EGFR-TKI treatment. All patients subsequently received dabrafenib, trametinib and osimertinib treatment. Clinical characteristics were documented, and progression-free survival (PFS) and adverse events (AEs) were assessed. In vivo drug response of PDOs were observed concurrently. Next-generation sequencing (NGS) was performed upon progression to triple-targeted therapy. Twelve patients with NGS-detected acquired BRAF V600E mutations were included in the study. Following triple-targeted therapy, the corresponding objective response rate (ORR) and disease control rate (DCR) was 58.3%, and 83.3%, respectively. The median PFS was 13.5 (95% CI: 9.8-17.2) months. No patients discontinued the treatment due to severe AEs. PDOs derived from one patient’s tumor sample were established, revealing that the triple-targeted therapy demonstrated a significantly lower IC50 value compared to other regimens. The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib plus osimertinib, 99.25% for osimertinib plus vemurafenib, 98.92% for osimertinib, encorafenib plus cetuximab, and 62.83% for pemetrexed plus carboplatin, respectively. NGS analysis identified major resistance mechanism following triple-targeted therapy, including EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and off-target mechanism. EGFR/BRAF/MEK triple-targeted therapy is an effective and safety approach for treating acquired BRAF V600E mutation in EGFR-mutant NSCLC patients resistant to EGFR-TKIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
lc完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
1秒前
2秒前
科研女郎完成签到 ,获得积分10
2秒前
2秒前
NexusExplorer应助1498626960采纳,获得10
2秒前
2秒前
JasVe完成签到 ,获得积分10
2秒前
cza完成签到,获得积分10
3秒前
好好学习的小学生完成签到,获得积分10
3秒前
张宇发布了新的文献求助10
4秒前
Drgao0606发布了新的文献求助10
4秒前
4秒前
4秒前
钱多多完成签到,获得积分20
4秒前
5秒前
迅速冥茗完成签到,获得积分10
5秒前
wsatm发布了新的文献求助10
5秒前
嘻嘻哈哈发布了新的文献求助10
6秒前
yurun_wu发布了新的文献求助10
6秒前
脑洞疼应助俊哥采纳,获得10
6秒前
麋鹿发布了新的文献求助10
6秒前
在水一方应助无昵称采纳,获得10
7秒前
yang完成签到,获得积分10
7秒前
7秒前
8秒前
钱多多发布了新的文献求助10
9秒前
kyukyubiu完成签到,获得积分10
10秒前
曾经不言发布了新的文献求助10
11秒前
妮妮完成签到,获得积分10
11秒前
自由如风完成签到 ,获得积分10
11秒前
檀熹发布了新的文献求助10
11秒前
wlj发布了新的文献求助10
12秒前
的墨完成签到,获得积分10
12秒前
12秒前
小铭完成签到,获得积分10
12秒前
12秒前
Crush完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968964
求助须知:如何正确求助?哪些是违规求助? 3513877
关于积分的说明 11170569
捐赠科研通 3249201
什么是DOI,文献DOI怎么找? 1794692
邀请新用户注册赠送积分活动 875297
科研通“疑难数据库(出版商)”最低求助积分说明 804755